MedTrace Logo

Probiotics in Advanced Urothelial Carcinoma

NCT06904573 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2025-04-01

No results posted yet for this study

Summary

This is a multicenter, randomized, controlled phase II Study of evaluating the efficacy and safety of immunotherapy combined with probiotics compound (Biolosion) in patients with advanced urothelial carcinoma.

Conditions

  • Advanced Urothelial Carcinoma
  • Probiotics
  • Immunotherapy

Interventions

DRUG

Probiotics Compound (Biolosion)

15g, PO, qd

DRUG

Nab-paclitaxel

230mg/m2, IV, days 1, 8, q3w

DRUG

Cisplatin

70mg/m2, IV, days 1-3, q3w

DRUG

Gemcitabine

1.2g/m2, IV, days 1, 8, q3w

DRUG

Disitamab vedotin

2.5mg/kg, IV, q2w

DRUG

Enfortumab Vedotin

1.25mg/kg, IV, days 1, 8, q3w

DRUG

Pembrolizumab

200mg, IV, q3w

DRUG

Toripalimab

240mg, IV, q3w

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Yanxia Shi, Doctor · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2027-01-01
Completion
2028-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06904573 on ClinicalTrials.gov